CogGen science is robust, validated and has been developed and tested using thousands of samples. Our scientific approach is supported by 20+ peer reviewed publications and 2 pending patents.

Cognitive Genetics LLC (CogGen) is a pre-commercial consumer healthcare company developing the first pre-symptomatic genetic screening panel for predisposition to the three most common Learning Disabilities (LDs):

  • Reading Disability (Dyslexia)
  • Specific Language Impairment (SLI)
  • Speech Sound Disorder (SSD)

CogGen's proprietary technology combined with it's unique quantitative modeling allows pre-symptomatic screening resulting in early intervention for those impaired with these common learning disabilities.

Early intervention, specifically in reading-age children (1st-3rd grade), is scientifically shown to dramatically improve academic performance, self-confidence and self-image, leading to significant and lasting improvements in long-term quality of life.

Cognitive Genetics LLC (CogGen) was founded in 2017 to commercialize technology developed at a leading research university with a goal to remove obstacles for children facing learning disabilities.